Monoclonal antibody (Mab) sB24M ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 269 | Pyogenic arthritis | 1 |
269. Pyogenic arthritis
Clinical trials : 23 / Drugs : 30 - (DrugBank : 12) / Drug target genes : 15 - Drug target pathways : 106
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04895566 (ClinicalTrials.gov) | May 24, 2021 | 17/5/2021 | Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma | Phase 0/1 Topical Application of the Monoclonal Antibody (Mab) sB24M in Patients With Severe Pyoderma | Pyoderma;Pyoderma Gangrenosum;Pyoderma Vegetans;Pyoderma Gangrenosum Surrounding Surgical Stoma | Biological: Monoclonal antibody (Mab) sB24M | SWISS BIOPHARMA MED GmbH | NULL | Active, not recruiting | 21 Years | 80 Years | All | 10 | Early Phase 1 | Belarus;Latvia |